| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epidermolysis Bullosa Dystrophica | 35 | 2025 | 46 | 14.190 |
Why?
|
| Collagen Type VII | 22 | 2024 | 29 | 5.750 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 38 | 2025 | 1258 | 3.170 |
Why?
|
| Skin | 19 | 2025 | 549 | 2.990 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 8 | 2021 | 81 | 2.590 |
Why?
|
| Mucopolysaccharidosis I | 17 | 2022 | 23 | 2.380 |
Why?
|
| Induced Pluripotent Stem Cells | 14 | 2025 | 251 | 2.320 |
Why?
|
| Genetic Therapy | 16 | 2025 | 724 | 2.220 |
Why?
|
| CRISPR-Cas Systems | 10 | 2025 | 303 | 1.890 |
Why?
|
| Graft vs Host Disease | 20 | 2025 | 678 | 1.770 |
Why?
|
| Bone Marrow Transplantation | 15 | 2023 | 594 | 1.700 |
Why?
|
| Gene Editing | 12 | 2025 | 222 | 1.610 |
Why?
|
| Fanconi Anemia | 6 | 2024 | 48 | 1.340 |
Why?
|
| Regenerative Medicine | 4 | 2018 | 39 | 1.270 |
Why?
|
| Keratinocytes | 11 | 2024 | 74 | 1.250 |
Why?
|
| Fibroblasts | 14 | 2024 | 861 | 1.250 |
Why?
|
| Fetal Blood | 5 | 2015 | 181 | 1.220 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2024 | 756 | 1.180 |
Why?
|
| Epidermolysis Bullosa | 3 | 2015 | 29 | 1.170 |
Why?
|
| Cell Engineering | 2 | 2019 | 21 | 1.170 |
Why?
|
| Wound Healing | 7 | 2023 | 476 | 1.130 |
Why?
|
| Disease Models, Animal | 18 | 2024 | 4686 | 1.080 |
Why?
|
| Genes, Recessive | 7 | 2024 | 201 | 1.070 |
Why?
|
| Pluripotent Stem Cells | 4 | 2017 | 74 | 1.060 |
Why?
|
| Skin Neoplasms | 3 | 2024 | 897 | 1.050 |
Why?
|
| Animals | 74 | 2025 | 34349 | 0.960 |
Why?
|
| Transplantation, Homologous | 15 | 2025 | 675 | 0.940 |
Why?
|
| Humans | 133 | 2025 | 131151 | 0.910 |
Why?
|
| Mice | 57 | 2025 | 18449 | 0.910 |
Why?
|
| Genetic Engineering | 3 | 2015 | 162 | 0.890 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2024 | 31 | 0.890 |
Why?
|
| Stem Cell Transplantation | 4 | 2017 | 236 | 0.870 |
Why?
|
| Precision Medicine | 4 | 2018 | 372 | 0.870 |
Why?
|
| Osteopetrosis | 2 | 2019 | 14 | 0.850 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2024 | 138 | 0.850 |
Why?
|
| Osteoclasts | 2 | 2019 | 71 | 0.820 |
Why?
|
| Adrenoleukodystrophy | 6 | 2018 | 12 | 0.820 |
Why?
|
| Cell Differentiation | 18 | 2025 | 1946 | 0.790 |
Why?
|
| Frameshift Mutation | 1 | 2024 | 201 | 0.790 |
Why?
|
| Neoplasm Invasiveness | 1 | 2024 | 645 | 0.770 |
Why?
|
| Enzyme Replacement Therapy | 7 | 2019 | 24 | 0.750 |
Why?
|
| Spinocerebellar Ataxias | 2 | 2022 | 259 | 0.740 |
Why?
|
| Cells, Cultured | 22 | 2024 | 2970 | 0.740 |
Why?
|
| T-Lymphocytes | 14 | 2025 | 1772 | 0.740 |
Why?
|
| Stromal Cells | 4 | 2011 | 315 | 0.730 |
Why?
|
| Bioprinting | 1 | 2021 | 13 | 0.720 |
Why?
|
| Skin Diseases | 2 | 2025 | 140 | 0.700 |
Why?
|
| Epidermolysis Bullosa, Junctional | 1 | 2020 | 4 | 0.650 |
Why?
|
| Dermatology | 2 | 2018 | 33 | 0.640 |
Why?
|
| Stem Cells | 5 | 2017 | 711 | 0.630 |
Why?
|
| Targeted Gene Repair | 1 | 2019 | 4 | 0.620 |
Why?
|
| Vacuolar Proton-Translocating ATPases | 1 | 2019 | 23 | 0.620 |
Why?
|
| MicroRNAs | 3 | 2016 | 893 | 0.600 |
Why?
|
| Iduronidase | 8 | 2019 | 9 | 0.590 |
Why?
|
| Transforming Growth Factor beta | 2 | 2024 | 464 | 0.580 |
Why?
|
| Transplantation Conditioning | 11 | 2024 | 329 | 0.570 |
Why?
|
| Teratoma | 1 | 2019 | 123 | 0.560 |
Why?
|
| Gene Transfer Techniques | 7 | 2025 | 343 | 0.560 |
Why?
|
| Killer Cells, Natural | 4 | 2016 | 344 | 0.560 |
Why?
|
| Protein Engineering | 2 | 2023 | 62 | 0.550 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2015 | 91 | 0.550 |
Why?
|
| Cell Culture Techniques | 3 | 2018 | 275 | 0.540 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 2 | 2017 | 83 | 0.540 |
Why?
|
| Feeder Cells | 1 | 2017 | 9 | 0.540 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 55 | 0.520 |
Why?
|
| T-Lymphocytes, Regulatory | 6 | 2023 | 234 | 0.520 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2014 | 26 | 0.520 |
Why?
|
| Dyskeratosis Congenita | 4 | 2024 | 23 | 0.520 |
Why?
|
| Transfection | 7 | 2019 | 961 | 0.500 |
Why?
|
| Disease | 1 | 2018 | 125 | 0.500 |
Why?
|
| Nerve Tissue Proteins | 1 | 2022 | 1124 | 0.500 |
Why?
|
| Plasmids | 7 | 2020 | 455 | 0.490 |
Why?
|
| Stem Cell Factor | 1 | 2015 | 12 | 0.480 |
Why?
|
| Phenotype | 4 | 2024 | 4497 | 0.480 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2015 | 6 | 0.470 |
Why?
|
| Cord Blood Stem Cell Transplantation | 4 | 2015 | 58 | 0.470 |
Why?
|
| Endonucleases | 2 | 2015 | 51 | 0.460 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2018 | 157 | 0.460 |
Why?
|
| Fanconi Anemia Complementation Group C Protein | 1 | 2015 | 3 | 0.450 |
Why?
|
| Deoxyribonuclease I | 1 | 2015 | 25 | 0.450 |
Why?
|
| Heterocyclic Compounds | 1 | 2014 | 19 | 0.440 |
Why?
|
| Drugs, Investigational | 1 | 2014 | 27 | 0.440 |
Why?
|
| Biomarkers | 8 | 2019 | 3379 | 0.440 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2022 | 153 | 0.430 |
Why?
|
| Mice, Inbred C57BL | 21 | 2025 | 4752 | 0.430 |
Why?
|
| Tacrolimus | 1 | 2014 | 104 | 0.420 |
Why?
|
| Signal Transduction | 2 | 2024 | 4655 | 0.410 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2018 | 464 | 0.410 |
Why?
|
| Basement Membrane | 2 | 2015 | 40 | 0.410 |
Why?
|
| Bone Marrow Cells | 5 | 2016 | 246 | 0.410 |
Why?
|
| Male | 50 | 2024 | 64940 | 0.400 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 1988 | 0.400 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2014 | 125 | 0.390 |
Why?
|
| Blood Platelets | 2 | 2015 | 316 | 0.390 |
Why?
|
| Hematopoietic Stem Cells | 7 | 2021 | 552 | 0.390 |
Why?
|
| Mice, Knockout | 15 | 2025 | 3860 | 0.390 |
Why?
|
| Biomedical Research | 2 | 2018 | 555 | 0.380 |
Why?
|
| DNA Repair | 1 | 2016 | 563 | 0.380 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2018 | 945 | 0.380 |
Why?
|
| Multipotent Stem Cells | 3 | 2009 | 27 | 0.370 |
Why?
|
| Fanconi Anemia Complementation Group A Protein | 1 | 2012 | 3 | 0.370 |
Why?
|
| Heart Diseases | 3 | 2016 | 505 | 0.370 |
Why?
|
| Hexosaminidases | 1 | 2011 | 7 | 0.360 |
Why?
|
| Mosaicism | 1 | 2013 | 242 | 0.360 |
Why?
|
| Proto-Oncogene Proteins c-bcr | 1 | 2011 | 11 | 0.360 |
Why?
|
| Child | 31 | 2024 | 26117 | 0.360 |
Why?
|
| Cell Line | 5 | 2022 | 2601 | 0.350 |
Why?
|
| Tumor Microenvironment | 2 | 2018 | 697 | 0.350 |
Why?
|
| Child, Preschool | 25 | 2024 | 14952 | 0.350 |
Why?
|
| Blood Transfusion | 1 | 2013 | 290 | 0.350 |
Why?
|
| Inflammasomes | 3 | 2025 | 156 | 0.350 |
Why?
|
| Cell Movement | 4 | 2024 | 876 | 0.350 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2011 | 69 | 0.350 |
Why?
|
| Genome | 2 | 2015 | 473 | 0.350 |
Why?
|
| Genetic Vectors | 6 | 2025 | 902 | 0.340 |
Why?
|
| Zinc Fingers | 1 | 2011 | 119 | 0.340 |
Why?
|
| Myocardial Ischemia | 2 | 2020 | 312 | 0.340 |
Why?
|
| Bone Marrow Diseases | 4 | 2024 | 45 | 0.340 |
Why?
|
| Placenta | 1 | 2015 | 529 | 0.330 |
Why?
|
| Cell Hypoxia | 1 | 2010 | 86 | 0.330 |
Why?
|
| Myeloproliferative Disorders | 1 | 2011 | 92 | 0.330 |
Why?
|
| Mutation | 9 | 2022 | 6155 | 0.320 |
Why?
|
| Mice, Inbred NOD | 5 | 2021 | 301 | 0.320 |
Why?
|
| Thymus Gland | 2 | 2022 | 102 | 0.320 |
Why?
|
| Hereditary Central Nervous System Demyelinating Diseases | 1 | 2010 | 20 | 0.320 |
Why?
|
| Translocation, Genetic | 1 | 2011 | 350 | 0.310 |
Why?
|
| Cytokines | 2 | 2023 | 1346 | 0.310 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2011 | 245 | 0.300 |
Why?
|
| Bacterial Proteins | 1 | 2015 | 934 | 0.300 |
Why?
|
| Acidosis, Lactic | 1 | 2009 | 30 | 0.300 |
Why?
|
| Transplantation, Autologous | 2 | 2019 | 272 | 0.300 |
Why?
|
| DNA Methylation | 1 | 2015 | 1083 | 0.290 |
Why?
|
| Female | 43 | 2024 | 70858 | 0.290 |
Why?
|
| Transposases | 2 | 2025 | 44 | 0.290 |
Why?
|
| Clinical Trials as Topic | 4 | 2015 | 1134 | 0.280 |
Why?
|
| HEK293 Cells | 6 | 2025 | 805 | 0.280 |
Why?
|
| Lipids | 3 | 2020 | 567 | 0.280 |
Why?
|
| Hypoglycemia | 1 | 2009 | 180 | 0.270 |
Why?
|
| Genome, Human | 1 | 2015 | 1331 | 0.270 |
Why?
|
| Inflammation | 1 | 2015 | 1487 | 0.270 |
Why?
|
| Adult Stem Cells | 2 | 2009 | 55 | 0.270 |
Why?
|
| Dependovirus | 2 | 2020 | 156 | 0.270 |
Why?
|
| Adolescent | 22 | 2024 | 20835 | 0.270 |
Why?
|
| Glycosaminoglycans | 9 | 2022 | 38 | 0.260 |
Why?
|
| Cell Transplantation | 1 | 2007 | 36 | 0.260 |
Why?
|
| Lysosomal Storage Diseases | 1 | 2007 | 38 | 0.260 |
Why?
|
| Primary Cell Culture | 2 | 2019 | 107 | 0.260 |
Why?
|
| Hemoglobinuria, Paroxysmal | 2 | 2017 | 23 | 0.260 |
Why?
|
| Age Factors | 4 | 2018 | 2869 | 0.250 |
Why?
|
| Gene Deletion | 2 | 2022 | 773 | 0.250 |
Why?
|
| Anemia, Aplastic | 2 | 2017 | 61 | 0.250 |
Why?
|
| Heart | 2 | 2010 | 679 | 0.250 |
Why?
|
| Immunomodulation | 2 | 2021 | 80 | 0.250 |
Why?
|
| Myocardium | 2 | 2010 | 886 | 0.240 |
Why?
|
| Immune Tolerance | 2 | 2025 | 159 | 0.240 |
Why?
|
| Gene Expression | 7 | 2020 | 1503 | 0.240 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2025 | 15 | 0.230 |
Why?
|
| Directed Molecular Evolution | 1 | 2025 | 12 | 0.230 |
Why?
|
| DNA Demethylation | 1 | 2025 | 10 | 0.230 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2025 | 52 | 0.230 |
Why?
|
| B7 Antigens | 1 | 2025 | 15 | 0.230 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2025 | 76 | 0.230 |
Why?
|
| Brain | 3 | 2023 | 3169 | 0.230 |
Why?
|
| Infant | 19 | 2024 | 13215 | 0.220 |
Why?
|
| Transplantation, Heterologous | 2 | 2016 | 261 | 0.220 |
Why?
|
| Dioxygenases | 1 | 2025 | 72 | 0.220 |
Why?
|
| Mucopolysaccharidoses | 3 | 2017 | 6 | 0.220 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2025 | 598 | 0.220 |
Why?
|
| Smad3 Protein | 1 | 2024 | 56 | 0.220 |
Why?
|
| Silicon | 1 | 2024 | 13 | 0.220 |
Why?
|
| Mutagenesis, Insertional | 1 | 2025 | 152 | 0.220 |
Why?
|
| Rats, Inbred Lew | 1 | 2024 | 67 | 0.210 |
Why?
|
| Recombinases | 1 | 2024 | 28 | 0.210 |
Why?
|
| Blister | 1 | 2024 | 21 | 0.210 |
Why?
|
| Membrane Proteins | 3 | 2025 | 1613 | 0.210 |
Why?
|
| Leukocyte Common Antigens | 1 | 2024 | 84 | 0.210 |
Why?
|
| Nucleic Acids | 1 | 2024 | 26 | 0.210 |
Why?
|
| Microsatellite Instability | 1 | 2024 | 37 | 0.210 |
Why?
|
| Adoptive Transfer | 3 | 2018 | 235 | 0.210 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2021 | 357 | 0.210 |
Why?
|
| Immunoconjugates | 1 | 2024 | 50 | 0.210 |
Why?
|
| Gene Knockout Techniques | 2 | 2022 | 136 | 0.210 |
Why?
|
| Hematologic Neoplasms | 3 | 2018 | 311 | 0.200 |
Why?
|
| Exons | 2 | 2024 | 767 | 0.200 |
Why?
|
| Receptors, CXCR4 | 2 | 2021 | 71 | 0.200 |
Why?
|
| Regeneration | 2 | 2020 | 230 | 0.200 |
Why?
|
| Unrelated Donors | 2 | 2021 | 75 | 0.200 |
Why?
|
| Allografts | 2 | 2022 | 207 | 0.200 |
Why?
|
| Treatment Outcome | 16 | 2020 | 12885 | 0.200 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2024 | 129 | 0.200 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2024 | 262 | 0.200 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2018 | 496 | 0.200 |
Why?
|
| Diagnostic Imaging | 1 | 2005 | 297 | 0.200 |
Why?
|
| Genotype | 4 | 2019 | 2651 | 0.200 |
Why?
|
| Galactosidases | 1 | 2022 | 7 | 0.190 |
Why?
|
| Ataxin-7 | 1 | 2022 | 15 | 0.190 |
Why?
|
| Membrane Glycoproteins | 3 | 2019 | 422 | 0.190 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2003 | 63 | 0.190 |
Why?
|
| Computational Biology | 2 | 2018 | 871 | 0.190 |
Why?
|
| Cytosine | 1 | 2022 | 53 | 0.190 |
Why?
|
| Antigens, CD19 | 2 | 2018 | 188 | 0.190 |
Why?
|
| Disease Transmission, Infectious | 1 | 2003 | 77 | 0.190 |
Why?
|
| Keratin-15 | 1 | 2022 | 1 | 0.190 |
Why?
|
| Trinucleotide Repeats | 1 | 2022 | 106 | 0.190 |
Why?
|
| Blood Coagulation Factors | 1 | 2022 | 32 | 0.180 |
Why?
|
| Bacteriophages | 1 | 2023 | 92 | 0.180 |
Why?
|
| Trans-Activators | 2 | 2022 | 690 | 0.180 |
Why?
|
| Vidarabine | 2 | 2024 | 90 | 0.180 |
Why?
|
| Myocytes, Cardiac | 2 | 2020 | 669 | 0.180 |
Why?
|
| Immunoglobulin G | 1 | 2025 | 809 | 0.180 |
Why?
|
| Graft Rejection | 3 | 2021 | 573 | 0.180 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2009 | 837 | 0.180 |
Why?
|
| Receptors, CCR5 | 1 | 2021 | 30 | 0.180 |
Why?
|
| Alopecia | 1 | 2022 | 42 | 0.180 |
Why?
|
| Young Adult | 12 | 2024 | 10049 | 0.180 |
Why?
|
| Survival Analysis | 7 | 2018 | 1524 | 0.180 |
Why?
|
| Aurora Kinase A | 1 | 2021 | 36 | 0.180 |
Why?
|
| Endothelial Cells | 2 | 2018 | 537 | 0.180 |
Why?
|
| Cell Proliferation | 6 | 2021 | 2464 | 0.180 |
Why?
|
| Bone Marrow | 2 | 2021 | 314 | 0.170 |
Why?
|
| Technology | 1 | 2021 | 70 | 0.170 |
Why?
|
| Case-Control Studies | 3 | 2020 | 3435 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 3 | 2025 | 1007 | 0.170 |
Why?
|
| Quinine | 1 | 2020 | 9 | 0.170 |
Why?
|
| Acrylates | 1 | 2020 | 10 | 0.170 |
Why?
|
| Reperfusion | 1 | 2020 | 26 | 0.170 |
Why?
|
| Advanced Cardiac Life Support | 1 | 2020 | 18 | 0.170 |
Why?
|
| Cerebellum | 2 | 2018 | 456 | 0.170 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2003 | 260 | 0.170 |
Why?
|
| Medicine | 1 | 2022 | 102 | 0.170 |
Why?
|
| Aging, Premature | 2 | 2018 | 32 | 0.170 |
Why?
|
| Adult | 16 | 2024 | 31607 | 0.170 |
Why?
|
| Anemia, Diamond-Blackfan | 2 | 2017 | 12 | 0.160 |
Why?
|
| Neoplasm Metastasis | 1 | 2003 | 704 | 0.160 |
Why?
|
| Ventricular Fibrillation | 1 | 2020 | 58 | 0.160 |
Why?
|
| Side-Population Cells | 1 | 2020 | 13 | 0.160 |
Why?
|
| Triterpenes | 1 | 2020 | 22 | 0.160 |
Why?
|
| Base Sequence | 3 | 2015 | 2781 | 0.160 |
Why?
|
| Retinoblastoma | 1 | 2021 | 87 | 0.160 |
Why?
|
| Telomere | 4 | 2024 | 220 | 0.160 |
Why?
|
| Ambroxol | 1 | 2019 | 5 | 0.160 |
Why?
|
| Skin Transplantation | 1 | 2020 | 58 | 0.160 |
Why?
|
| Corpus Callosum | 1 | 2020 | 104 | 0.160 |
Why?
|
| Gaucher Disease | 1 | 2019 | 13 | 0.160 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2019 | 26 | 0.160 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2018 | 691 | 0.160 |
Why?
|
| Amyloidosis, Familial | 1 | 2019 | 2 | 0.150 |
Why?
|
| Lymphocyte Depletion | 3 | 2010 | 122 | 0.150 |
Why?
|
| Molecular Sequence Data | 3 | 2015 | 3611 | 0.150 |
Why?
|
| Genetic Loci | 3 | 2017 | 356 | 0.150 |
Why?
|
| Neurofibromin 1 | 1 | 2019 | 49 | 0.150 |
Why?
|
| Myelin Sheath | 1 | 2020 | 126 | 0.150 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 369 | 0.150 |
Why?
|
| Genes, Reporter | 4 | 2016 | 350 | 0.150 |
Why?
|
| Skin Diseases, Genetic | 1 | 2019 | 21 | 0.150 |
Why?
|
| Antibodies | 2 | 2019 | 357 | 0.150 |
Why?
|
| Cell Cycle | 2 | 2021 | 600 | 0.150 |
Why?
|
| Oxidative Stress | 2 | 2017 | 802 | 0.150 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2020 | 97 | 0.150 |
Why?
|
| Lentivirus | 1 | 2019 | 81 | 0.150 |
Why?
|
| Cell Line, Tumor | 3 | 2024 | 3670 | 0.150 |
Why?
|
| Injections, Spinal | 1 | 2019 | 132 | 0.150 |
Why?
|
| Neurofibromatosis 1 | 1 | 2019 | 66 | 0.150 |
Why?
|
| Thymocytes | 1 | 2018 | 10 | 0.150 |
Why?
|
| Cell Adhesion Molecules | 1 | 2020 | 227 | 0.150 |
Why?
|
| Trehalose | 1 | 2018 | 21 | 0.150 |
Why?
|
| Neoplasm, Residual | 1 | 2019 | 137 | 0.150 |
Why?
|
| Immunity, Innate | 1 | 2021 | 411 | 0.150 |
Why?
|
| Glucuronidase | 1 | 2018 | 30 | 0.150 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 530 | 0.140 |
Why?
|
| Mice, SCID | 4 | 2014 | 579 | 0.140 |
Why?
|
| Societies, Scientific | 1 | 2018 | 25 | 0.140 |
Why?
|
| Zebrafish | 6 | 2021 | 422 | 0.140 |
Why?
|
| Wills | 1 | 2018 | 2 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 1 | 2022 | 1218 | 0.140 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2018 | 10 | 0.140 |
Why?
|
| Chemokines, CC | 1 | 2018 | 26 | 0.140 |
Why?
|
| Models, Genetic | 3 | 2018 | 750 | 0.140 |
Why?
|
| Replication Origin | 1 | 2017 | 12 | 0.140 |
Why?
|
| Rats | 1 | 2024 | 3461 | 0.140 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2016 | 265 | 0.140 |
Why?
|
| Haplotypes | 2 | 2021 | 543 | 0.140 |
Why?
|
| Microvessels | 1 | 2018 | 66 | 0.130 |
Why?
|
| DNA | 2 | 2022 | 1444 | 0.130 |
Why?
|
| Tissue Scaffolds | 1 | 2018 | 93 | 0.130 |
Why?
|
| Patient-Specific Modeling | 1 | 2017 | 11 | 0.130 |
Why?
|
| Homeodomain Proteins | 1 | 2021 | 566 | 0.130 |
Why?
|
| Polyamines | 1 | 2017 | 37 | 0.130 |
Why?
|
| PAX7 Transcription Factor | 1 | 2017 | 21 | 0.130 |
Why?
|
| Single-Cell Analysis | 2 | 2018 | 369 | 0.130 |
Why?
|
| Syndecan-2 | 1 | 2017 | 10 | 0.130 |
Why?
|
| Ataxin-1 | 1 | 2018 | 161 | 0.130 |
Why?
|
| Heparin | 1 | 2018 | 208 | 0.130 |
Why?
|
| Gain of Function Mutation | 1 | 2018 | 114 | 0.130 |
Why?
|
| Blood-Brain Barrier | 1 | 2018 | 147 | 0.130 |
Why?
|
| GATA1 Transcription Factor | 1 | 2017 | 10 | 0.130 |
Why?
|
| Vitiligo | 1 | 2017 | 10 | 0.130 |
Why?
|
| Printing, Three-Dimensional | 1 | 2018 | 89 | 0.130 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2017 | 120 | 0.130 |
Why?
|
| Long Term Adverse Effects | 1 | 2017 | 14 | 0.130 |
Why?
|
| Muscle Development | 1 | 2017 | 68 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2010 | 517 | 0.130 |
Why?
|
| Integrins | 1 | 2017 | 90 | 0.130 |
Why?
|
| Embryonic Stem Cells | 1 | 2018 | 160 | 0.130 |
Why?
|
| Cell Tracking | 1 | 2016 | 16 | 0.130 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 245 | 0.130 |
Why?
|
| DNA-Binding Proteins | 1 | 2025 | 1958 | 0.130 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2017 | 23 | 0.130 |
Why?
|
| Pigmentation Disorders | 1 | 2017 | 23 | 0.130 |
Why?
|
| Luminescent Measurements | 1 | 2016 | 56 | 0.130 |
Why?
|
| Erythroid Cells | 1 | 2017 | 25 | 0.130 |
Why?
|
| Epigenesis, Genetic | 2 | 2013 | 749 | 0.130 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2017 | 31 | 0.130 |
Why?
|
| Cluster Analysis | 1 | 2018 | 419 | 0.130 |
Why?
|
| Immunophenotyping | 2 | 2015 | 337 | 0.130 |
Why?
|
| B-Lymphocytes | 2 | 2018 | 527 | 0.130 |
Why?
|
| CD28 Antigens | 1 | 2016 | 75 | 0.130 |
Why?
|
| Models, Biological | 3 | 2018 | 1392 | 0.130 |
Why?
|
| Mitochondria | 3 | 2021 | 765 | 0.130 |
Why?
|
| Corneal Opacity | 1 | 2016 | 21 | 0.120 |
Why?
|
| Sp1 Transcription Factor | 1 | 2016 | 37 | 0.120 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2016 | 25 | 0.120 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 129 | 0.120 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2016 | 3 | 0.120 |
Why?
|
| Genetic Markers | 1 | 2018 | 605 | 0.120 |
Why?
|
| Tissue Culture Techniques | 1 | 2016 | 65 | 0.120 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2016 | 18 | 0.120 |
Why?
|
| Transcription Activator-Like Effector Nucleases | 1 | 2015 | 4 | 0.120 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 834 | 0.120 |
Why?
|
| Endodermal Sinus Tumor | 1 | 2015 | 7 | 0.120 |
Why?
|
| Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase | 1 | 2015 | 7 | 0.120 |
Why?
|
| Culture Media | 1 | 2016 | 174 | 0.120 |
Why?
|
| Proteome | 1 | 2018 | 285 | 0.120 |
Why?
|
| Transcriptional Activation | 3 | 2023 | 415 | 0.120 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 61 | 0.120 |
Why?
|
| Fas Ligand Protein | 1 | 2015 | 36 | 0.120 |
Why?
|
| Genes, Homeobox | 1 | 2015 | 61 | 0.120 |
Why?
|
| DNA Replication | 1 | 2017 | 359 | 0.120 |
Why?
|
| Aging | 2 | 2024 | 1260 | 0.120 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2016 | 139 | 0.120 |
Why?
|
| Tissue Donors | 3 | 2018 | 512 | 0.120 |
Why?
|
| Purines | 1 | 2015 | 115 | 0.110 |
Why?
|
| Middle Aged | 10 | 2024 | 28781 | 0.110 |
Why?
|
| Interleukin-15 | 1 | 2016 | 102 | 0.110 |
Why?
|
| Electroporation | 1 | 2015 | 37 | 0.110 |
Why?
|
| Time Factors | 8 | 2020 | 6282 | 0.110 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 420 | 0.110 |
Why?
|
| Computer Simulation | 1 | 2018 | 686 | 0.110 |
Why?
|
| Gene Targeting | 2 | 2015 | 170 | 0.110 |
Why?
|
| Sequence Deletion | 1 | 2017 | 513 | 0.110 |
Why?
|
| Benzylamines | 1 | 2014 | 22 | 0.110 |
Why?
|
| Myeloid Cells | 1 | 2015 | 115 | 0.110 |
Why?
|
| Collagen | 1 | 2016 | 295 | 0.110 |
Why?
|
| Cell Plasticity | 1 | 2015 | 37 | 0.110 |
Why?
|
| Craniofacial Abnormalities | 1 | 2016 | 255 | 0.110 |
Why?
|
| Peripheral Nervous System | 1 | 2014 | 46 | 0.110 |
Why?
|
| RNA | 1 | 2018 | 531 | 0.110 |
Why?
|
| Epidermis | 1 | 2014 | 64 | 0.110 |
Why?
|
| DNA Transposable Elements | 2 | 2005 | 182 | 0.110 |
Why?
|
| Streptococcus pyogenes | 1 | 2015 | 81 | 0.110 |
Why?
|
| Fibrosis | 1 | 2016 | 417 | 0.110 |
Why?
|
| Adenoviridae | 2 | 2015 | 582 | 0.110 |
Why?
|
| Peripheral Nerves | 1 | 2014 | 87 | 0.110 |
Why?
|
| Proteomics | 2 | 2018 | 600 | 0.110 |
Why?
|
| Machine Learning | 1 | 2018 | 363 | 0.110 |
Why?
|
| Mast Cells | 1 | 2014 | 71 | 0.110 |
Why?
|
| Epithelial Cells | 1 | 2018 | 899 | 0.110 |
Why?
|
| Neutropenia | 1 | 2015 | 205 | 0.100 |
Why?
|
| Flow Cytometry | 4 | 2016 | 769 | 0.100 |
Why?
|
| United States Food and Drug Administration | 1 | 2014 | 156 | 0.100 |
Why?
|
| In Vitro Techniques | 3 | 2010 | 835 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2010 | 577 | 0.100 |
Why?
|
| Skin Diseases, Infectious | 1 | 2013 | 25 | 0.100 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 678 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 2 | 2015 | 1490 | 0.100 |
Why?
|
| Transcription Factors | 1 | 2023 | 2433 | 0.100 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2013 | 76 | 0.100 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 363 | 0.100 |
Why?
|
| Lymphocyte Activation | 5 | 2016 | 681 | 0.100 |
Why?
|
| Mice, Transgenic | 6 | 2018 | 2361 | 0.100 |
Why?
|
| Organoids | 1 | 2016 | 305 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 565 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 933 | 0.090 |
Why?
|
| Clinical Protocols | 1 | 2013 | 229 | 0.090 |
Why?
|
| Pericardial Effusion | 1 | 2013 | 72 | 0.090 |
Why?
|
| Hematopoiesis | 3 | 2011 | 219 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 739 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 383 | 0.090 |
Why?
|
| Pain | 1 | 2014 | 438 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2011 | 79 | 0.090 |
Why?
|
| Progeria | 1 | 2011 | 17 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2011 | 101 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2010 | 94 | 0.090 |
Why?
|
| Recombinant Proteins | 3 | 2023 | 1314 | 0.090 |
Why?
|
| Chimerism | 1 | 2011 | 29 | 0.090 |
Why?
|
| Chemokine CXCL12 | 1 | 2011 | 36 | 0.090 |
Why?
|
| Cellular Senescence | 2 | 2010 | 221 | 0.090 |
Why?
|
| Addison Disease | 1 | 2011 | 4 | 0.090 |
Why?
|
| Oligonucleotides | 1 | 2011 | 96 | 0.090 |
Why?
|
| Immunosuppressive Agents | 3 | 2016 | 671 | 0.090 |
Why?
|
| Algorithms | 1 | 2018 | 1681 | 0.090 |
Why?
|
| Adrenergic beta-1 Receptor Agonists | 1 | 2010 | 3 | 0.090 |
Why?
|
| Stem Cell Niche | 1 | 2011 | 57 | 0.090 |
Why?
|
| Metalloendopeptidases | 1 | 2011 | 101 | 0.080 |
Why?
|
| Anthracenes | 1 | 2010 | 9 | 0.080 |
Why?
|
| Biopsy | 1 | 2014 | 1249 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1828 | 0.080 |
Why?
|
| DNA, Circular | 1 | 2010 | 17 | 0.080 |
Why?
|
| Muscle Strength | 1 | 2011 | 82 | 0.080 |
Why?
|
| Neuromuscular Junction | 1 | 2011 | 96 | 0.080 |
Why?
|
| Reticulin | 1 | 2010 | 8 | 0.080 |
Why?
|
| Brain Chemistry | 1 | 2011 | 111 | 0.080 |
Why?
|
| Dobutamine | 1 | 2010 | 56 | 0.080 |
Why?
|
| Muscle Contraction | 1 | 2011 | 153 | 0.080 |
Why?
|
| Cognition | 2 | 2015 | 837 | 0.080 |
Why?
|
| Transplantation Chimera | 1 | 2010 | 46 | 0.080 |
Why?
|
| Adenine Nucleotides | 1 | 2010 | 37 | 0.080 |
Why?
|
| Arabinonucleosides | 1 | 2010 | 34 | 0.080 |
Why?
|
| Arginase | 1 | 2010 | 37 | 0.080 |
Why?
|
| Brain Diseases, Metabolic, Inborn | 1 | 2010 | 23 | 0.080 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2010 | 136 | 0.080 |
Why?
|
| Interleukin-13 | 1 | 2010 | 96 | 0.080 |
Why?
|
| Enzyme Activation | 1 | 2011 | 586 | 0.080 |
Why?
|
| Drug Resistance | 1 | 2011 | 249 | 0.080 |
Why?
|
| Leukodystrophy, Metachromatic | 1 | 2010 | 6 | 0.080 |
Why?
|
| Leukodystrophy, Globoid Cell | 1 | 2010 | 6 | 0.080 |
Why?
|
| Antigens, Surface | 1 | 2010 | 116 | 0.080 |
Why?
|
| Tricuspid Valve | 1 | 2010 | 63 | 0.080 |
Why?
|
| Lung | 1 | 2018 | 1575 | 0.080 |
Why?
|
| Neoplasms | 2 | 2023 | 2962 | 0.080 |
Why?
|
| Steroids | 1 | 2011 | 172 | 0.080 |
Why?
|
| Genomics | 1 | 2018 | 1618 | 0.080 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2009 | 14 | 0.080 |
Why?
|
| Microscopy, Acoustic | 1 | 2009 | 16 | 0.080 |
Why?
|
| Cell Survival | 2 | 2016 | 852 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 166 | 0.080 |
Why?
|
| Extremities | 1 | 2009 | 77 | 0.080 |
Why?
|
| Dinoprostone | 1 | 2009 | 68 | 0.070 |
Why?
|
| Intestines | 1 | 2013 | 585 | 0.070 |
Why?
|
| Antigen Presentation | 1 | 2009 | 118 | 0.070 |
Why?
|
| Antineoplastic Agents | 2 | 2011 | 1804 | 0.070 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2009 | 139 | 0.070 |
Why?
|
| Administration, Intravenous | 2 | 2019 | 170 | 0.070 |
Why?
|
| Telomerase | 1 | 2009 | 157 | 0.070 |
Why?
|
| Linear Models | 1 | 2010 | 694 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 3 | 2023 | 1020 | 0.070 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 240 | 0.070 |
Why?
|
| Blotting, Western | 1 | 2010 | 1021 | 0.070 |
Why?
|
| Luciferases | 2 | 2005 | 127 | 0.070 |
Why?
|
| Biomarkers, Pharmacological | 2 | 2019 | 16 | 0.070 |
Why?
|
| DNA Damage | 1 | 2012 | 527 | 0.070 |
Why?
|
| Mitral Valve | 1 | 2010 | 254 | 0.070 |
Why?
|
| Luminescent Proteins | 2 | 2005 | 157 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1237 | 0.070 |
Why?
|
| Retroelements | 1 | 2008 | 41 | 0.070 |
Why?
|
| Sphingolipidoses | 1 | 2007 | 3 | 0.070 |
Why?
|
| Mycophenolic Acid | 1 | 2008 | 60 | 0.070 |
Why?
|
| Propylene Glycols | 1 | 2007 | 20 | 0.070 |
Why?
|
| Sphingosine | 1 | 2007 | 23 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2025 | 1228 | 0.070 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 802 | 0.070 |
Why?
|
| Pregnancy | 2 | 2015 | 7563 | 0.070 |
Why?
|
| HLA-C Antigens | 1 | 2007 | 11 | 0.070 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 995 | 0.070 |
Why?
|
| HLA-B Antigens | 1 | 2007 | 30 | 0.070 |
Why?
|
| Interleukin-2 | 2 | 2023 | 238 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2024 | 6453 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2010 | 1567 | 0.060 |
Why?
|
| Biomechanical Phenomena | 2 | 2018 | 263 | 0.060 |
Why?
|
| Receptors, Immunologic | 1 | 2007 | 119 | 0.060 |
Why?
|
| Hemodynamics | 1 | 2010 | 839 | 0.060 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2009 | 359 | 0.060 |
Why?
|
| Antilymphocyte Serum | 1 | 2006 | 44 | 0.060 |
Why?
|
| Endostatins | 1 | 2006 | 10 | 0.060 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2006 | 23 | 0.060 |
Why?
|
| Carboplatin | 1 | 2006 | 79 | 0.060 |
Why?
|
| Whole-Body Irradiation | 1 | 2006 | 61 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2021 | 1443 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2025 | 459 | 0.060 |
Why?
|
| Cell Lineage | 2 | 2020 | 346 | 0.060 |
Why?
|
| Picornaviridae | 1 | 2005 | 19 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2016 | 5264 | 0.060 |
Why?
|
| Sex Factors | 1 | 2009 | 1343 | 0.060 |
Why?
|
| Mice, Inbred Strains | 1 | 2006 | 297 | 0.060 |
Why?
|
| Cysteine Endopeptidases | 1 | 2005 | 109 | 0.060 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2004 | 16 | 0.060 |
Why?
|
| Proton Pumps | 1 | 2004 | 12 | 0.060 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2004 | 17 | 0.060 |
Why?
|
| Carbonic Anhydrases | 1 | 2004 | 23 | 0.060 |
Why?
|
| Heterografts | 1 | 2025 | 194 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 1283 | 0.060 |
Why?
|
| Coculture Techniques | 2 | 2018 | 235 | 0.060 |
Why?
|
| Muscle, Skeletal | 1 | 2011 | 996 | 0.060 |
Why?
|
| Bone Resorption | 1 | 2004 | 52 | 0.050 |
Why?
|
| Leukemia | 1 | 2008 | 374 | 0.050 |
Why?
|
| Child Development | 2 | 2019 | 271 | 0.050 |
Why?
|
| RANK Ligand | 1 | 2004 | 52 | 0.050 |
Why?
|
| Lymphoma | 1 | 2008 | 328 | 0.050 |
Why?
|
| Chloride Channels | 1 | 2004 | 60 | 0.050 |
Why?
|
| Transgenes | 1 | 2005 | 324 | 0.050 |
Why?
|
| Porosity | 1 | 2024 | 43 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 2 | 2017 | 132 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 910 | 0.050 |
Why?
|
| Alemtuzumab | 1 | 2024 | 90 | 0.050 |
Why?
|
| Pruritus | 1 | 2024 | 49 | 0.050 |
Why?
|
| Nanotechnology | 1 | 2024 | 50 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 3075 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 3398 | 0.050 |
Why?
|
| Nanostructures | 1 | 2024 | 64 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2018 | 1250 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2025 | 154 | 0.050 |
Why?
|
| Viral Proteins | 1 | 2005 | 339 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2018 | 138 | 0.050 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2006 | 294 | 0.050 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2023 | 78 | 0.050 |
Why?
|
| Integrases | 1 | 2024 | 157 | 0.050 |
Why?
|
| Cytidine | 1 | 2022 | 12 | 0.050 |
Why?
|
| Deoxyadenosines | 1 | 2022 | 11 | 0.050 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2003 | 82 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2009 | 1270 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2005 | 567 | 0.050 |
Why?
|
| NIH 3T3 Cells | 2 | 2017 | 96 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 1626 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2024 | 439 | 0.050 |
Why?
|
| Neutrophils | 2 | 2015 | 371 | 0.050 |
Why?
|
| United States | 2 | 2014 | 11743 | 0.050 |
Why?
|
| Adenine | 1 | 2022 | 124 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2006 | 456 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2024 | 355 | 0.040 |
Why?
|
| Dilatation | 1 | 2022 | 70 | 0.040 |
Why?
|
| Community-Based Participatory Research | 1 | 2022 | 63 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2022 | 157 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2007 | 1741 | 0.040 |
Why?
|
| Schools, Medical | 1 | 2022 | 110 | 0.040 |
Why?
|
| Survival | 1 | 2020 | 15 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2021 | 95 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2019 | 5101 | 0.040 |
Why?
|
| K562 Cells | 1 | 2020 | 97 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2021 | 308 | 0.040 |
Why?
|
| Myelin Basic Protein | 1 | 2020 | 68 | 0.040 |
Why?
|
| Janus Kinase 2 | 1 | 2021 | 139 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 2021 | 205 | 0.040 |
Why?
|
| Cerebral Cortex | 1 | 2023 | 465 | 0.040 |
Why?
|
| Safety | 1 | 2020 | 215 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2019 | 34 | 0.040 |
Why?
|
| Graft Survival | 2 | 2015 | 465 | 0.040 |
Why?
|
| Survival Rate | 2 | 2015 | 2145 | 0.040 |
Why?
|
| Glucosylceramidase | 1 | 2019 | 27 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 569 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 3835 | 0.040 |
Why?
|
| Leadership | 1 | 2022 | 239 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2004 | 1022 | 0.040 |
Why?
|
| Transplants | 1 | 2019 | 38 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2020 | 695 | 0.040 |
Why?
|
| Adolescent Development | 1 | 2019 | 38 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2022 | 267 | 0.040 |
Why?
|
| Immobilized Proteins | 1 | 2018 | 6 | 0.040 |
Why?
|
| Transplantation | 1 | 2018 | 26 | 0.040 |
Why?
|
| Dermis | 1 | 2018 | 27 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2010 | 318 | 0.040 |
Why?
|
| Diet Therapy | 1 | 2018 | 41 | 0.040 |
Why?
|
| Leukocytes | 1 | 2019 | 211 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2011 | 830 | 0.040 |
Why?
|
| HIV-1 | 1 | 2021 | 476 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2018 | 72 | 0.030 |
Why?
|
| Aged | 4 | 2020 | 21172 | 0.030 |
Why?
|
| Spermine | 1 | 2017 | 7 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 741 | 0.030 |
Why?
|
| Electric Impedance | 1 | 2018 | 72 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2018 | 178 | 0.030 |
Why?
|
| Arabinonucleotides | 1 | 2017 | 1 | 0.030 |
Why?
|
| Infusions, Intravenous | 2 | 2010 | 549 | 0.030 |
Why?
|
| Lipid Droplets | 1 | 2018 | 51 | 0.030 |
Why?
|
| Macrophages | 1 | 2022 | 665 | 0.030 |
Why?
|
| Retina | 1 | 2021 | 460 | 0.030 |
Why?
|
| Cholesterol | 1 | 2020 | 543 | 0.030 |
Why?
|
| Spleen | 2 | 2009 | 256 | 0.030 |
Why?
|
| Hydrogels | 1 | 2018 | 101 | 0.030 |
Why?
|
| Fibroblast Growth Factors | 1 | 2018 | 169 | 0.030 |
Why?
|
| Retrospective Studies | 5 | 2015 | 17513 | 0.030 |
Why?
|
| Heterozygote | 1 | 2019 | 727 | 0.030 |
Why?
|
| Pulmonary Fibrosis | 1 | 2018 | 115 | 0.030 |
Why?
|
| Ergosterol | 1 | 2016 | 2 | 0.030 |
Why?
|
| Polymers | 1 | 2018 | 113 | 0.030 |
Why?
|
| Incidence | 2 | 2015 | 3331 | 0.030 |
Why?
|
| Melanocytes | 1 | 2017 | 45 | 0.030 |
Why?
|
| Survivors | 1 | 2019 | 351 | 0.030 |
Why?
|
| Central Nervous System Diseases | 1 | 2017 | 98 | 0.030 |
Why?
|
| Receptors, Angiotensin | 1 | 2016 | 20 | 0.030 |
Why?
|
| Vitamin D | 1 | 2018 | 189 | 0.030 |
Why?
|
| Losartan | 1 | 2016 | 35 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2020 | 505 | 0.030 |
Why?
|
| Facies | 1 | 2017 | 157 | 0.030 |
Why?
|
| Dogs | 1 | 2017 | 632 | 0.030 |
Why?
|
| International Cooperation | 1 | 2017 | 162 | 0.030 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2020 | 339 | 0.030 |
Why?
|
| Neuroprotective Agents | 1 | 2018 | 161 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2017 | 147 | 0.030 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2016 | 5 | 0.030 |
Why?
|
| Cell Death | 1 | 2017 | 237 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2017 | 230 | 0.030 |
Why?
|
| HL-60 Cells | 1 | 2016 | 33 | 0.030 |
Why?
|
| HT29 Cells | 1 | 2016 | 44 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2018 | 416 | 0.030 |
Why?
|
| Myofibroblasts | 1 | 2016 | 62 | 0.030 |
Why?
|
| Renin-Angiotensin System | 1 | 2016 | 105 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 436 | 0.030 |
Why?
|
| CD11 Antigens | 1 | 2015 | 11 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2015 | 99 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2018 | 542 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2015 | 59 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 2017 | 471 | 0.030 |
Why?
|
| Cyclosporine | 1 | 2016 | 130 | 0.030 |
Why?
|
| Cryopreservation | 1 | 2015 | 78 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2017 | 234 | 0.030 |
Why?
|
| Forecasting | 1 | 2017 | 364 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2016 | 496 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2015 | 93 | 0.030 |
Why?
|
| Homozygote | 1 | 2017 | 547 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2015 | 159 | 0.030 |
Why?
|
| Prognosis | 2 | 2014 | 4937 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2015 | 280 | 0.030 |
Why?
|
| Disease Progression | 2 | 2011 | 2201 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2015 | 227 | 0.030 |
Why?
|
| Consensus | 1 | 2017 | 567 | 0.030 |
Why?
|
| Quality of Life | 1 | 2024 | 2100 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 514 | 0.030 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2013 | 18 | 0.030 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 2013 | 18 | 0.030 |
Why?
|
| Siblings | 1 | 2014 | 204 | 0.030 |
Why?
|
| SEER Program | 1 | 2014 | 210 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2017 | 704 | 0.020 |
Why?
|
| Pericardiocentesis | 1 | 2013 | 17 | 0.020 |
Why?
|
| Pedigree | 1 | 2017 | 1703 | 0.020 |
Why?
|
| Tretinoin | 1 | 2013 | 96 | 0.020 |
Why?
|
| Binding Sites | 1 | 2015 | 1202 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 2563 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2013 | 155 | 0.020 |
Why?
|
| Protein Binding | 1 | 2015 | 1708 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2015 | 8543 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2011 | 62 | 0.020 |
Why?
|
| Acute Disease | 1 | 2014 | 1156 | 0.020 |
Why?
|
| Seasons | 1 | 2013 | 333 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2011 | 83 | 0.020 |
Why?
|
| Ankle Joint | 1 | 2011 | 35 | 0.020 |
Why?
|
| Range of Motion, Articular | 1 | 2011 | 83 | 0.020 |
Why?
|
| Immunity, Active | 1 | 2010 | 7 | 0.020 |
Why?
|
| Transcriptome | 1 | 2018 | 1151 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 2013 | 225 | 0.020 |
Why?
|
| Gene Order | 1 | 2010 | 81 | 0.020 |
Why?
|
| Adrenal Insufficiency | 1 | 2011 | 31 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 419 | 0.020 |
Why?
|
| B7-1 Antigen | 1 | 2010 | 12 | 0.020 |
Why?
|
| Cell Communication | 1 | 2011 | 195 | 0.020 |
Why?
|
| Physical Conditioning, Animal | 1 | 2011 | 86 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 1315 | 0.020 |
Why?
|
| Random Allocation | 1 | 2011 | 421 | 0.020 |
Why?
|
| CD8 Antigens | 1 | 2010 | 41 | 0.020 |
Why?
|
| Body Surface Area | 1 | 2010 | 37 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2010 | 70 | 0.020 |
Why?
|
| Gangliosides | 1 | 2011 | 74 | 0.020 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2010 | 69 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2011 | 191 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2011 | 331 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 292 | 0.020 |
Why?
|
| Minnesota | 1 | 2010 | 181 | 0.020 |
Why?
|
| Apoptosis | 1 | 2017 | 1861 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 690 | 0.020 |
Why?
|
| Diphtheria Toxin | 1 | 2009 | 15 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 2009 | 208 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 364 | 0.020 |
Why?
|
| Delayed Diagnosis | 1 | 2011 | 129 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 1834 | 0.020 |
Why?
|
| HIV Infections | 1 | 2021 | 2025 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 459 | 0.020 |
Why?
|
| Tumor Escape | 1 | 2009 | 63 | 0.020 |
Why?
|
| B7-H1 Antigen | 1 | 2010 | 131 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2009 | 365 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 1475 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2008 | 63 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2009 | 202 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 61 | 0.020 |
Why?
|
| Antigens, CD20 | 1 | 2008 | 43 | 0.020 |
Why?
|
| Mesoderm | 1 | 2008 | 107 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1615 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 373 | 0.020 |
Why?
|
| Cell Separation | 1 | 2008 | 221 | 0.020 |
Why?
|
| Receptors, KIR | 1 | 2007 | 11 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2007 | 60 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2010 | 285 | 0.020 |
Why?
|
| Isoantigens | 1 | 2007 | 25 | 0.020 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2007 | 36 | 0.020 |
Why?
|
| Transplantation Immunology | 1 | 2007 | 42 | 0.020 |
Why?
|
| Hematopoietic System | 1 | 2007 | 7 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2007 | 255 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2007 | 110 | 0.020 |
Why?
|
| Databases, Nucleic Acid | 1 | 2007 | 73 | 0.020 |
Why?
|
| Lymphoid Tissue | 1 | 2007 | 48 | 0.020 |
Why?
|
| Rituximab | 1 | 2008 | 173 | 0.020 |
Why?
|
| Peptides | 1 | 2010 | 835 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 61 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 793 | 0.020 |
Why?
|
| Neurons | 1 | 2016 | 1980 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 2133 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2007 | 160 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2007 | 400 | 0.020 |
Why?
|
| Body Weight | 1 | 2010 | 986 | 0.020 |
Why?
|
| Luciferases, Firefly | 1 | 2005 | 11 | 0.010 |
Why?
|
| Elastin | 1 | 2005 | 32 | 0.010 |
Why?
|
| Viremia | 1 | 2006 | 131 | 0.010 |
Why?
|
| Ligands | 1 | 2007 | 487 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2007 | 594 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2007 | 383 | 0.010 |
Why?
|
| Heart Valves | 1 | 2005 | 53 | 0.010 |
Why?
|
| Risk Factors | 2 | 2013 | 10923 | 0.010 |
Why?
|
| Genes | 1 | 2005 | 308 | 0.010 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2006 | 218 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2008 | 496 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2006 | 237 | 0.010 |
Why?
|
| Pericardium | 1 | 2005 | 107 | 0.010 |
Why?
|
| Internet | 1 | 2007 | 418 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2006 | 1001 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2005 | 579 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 2008 | 572 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 2357 | 0.010 |
Why?
|
| Alleles | 1 | 2007 | 1707 | 0.010 |
Why?
|
| Aorta | 1 | 2005 | 534 | 0.010 |
Why?
|
| Swine | 1 | 2005 | 1189 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 2005 | 531 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2005 | 963 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2007 | 2849 | 0.010 |
Why?
|